Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2007 | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $4.97B | — | — | — |
| Gross profit | $3.36B | $3.63B | $3.83B | $3.84B | $4.15B | $4.60B | $4.74B | — | — | — |
| Gross margin | — | — | — | — | — | — | 95.3% | — | — | — |
| Operating income | $1.58B | $1.67B | $1.76B | $1.92B | $2.07B | $2.22B | $2.26B | — | — | — |
| Operating margin | — | — | — | — | — | — | 45.4% | — | — | — |
| Net income | $717M | $818M | $891M | $979M | $1.07B | $1.19B | $1.11B | — | — | — |
| Net margin | — | — | — | — | — | — | 22.3% | — | — | — |
| EPS (diluted) | $2.42 | $2.74 | $2.99 | $3.24 | $3.51 | $3.87 | $3.65 | — | — | — |
| Fiscal year | FY2007 | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.20B | $1.02B | $1.34B | $1.37B | $1.45B | $2.04B | $2.03B | — | — | — |
| Capital expenditures | $573M | $687M | $574M | $524M | $598M | $675M | $748M | — | — | — |
| Free cash flow | $627M | $329M | $765M | $844M | $849M | $1.36B | $1.29B | — | — | — |
| Dividends paid | $188M | $252M | $232M | $232M | $281M | $272M | $296M | — | — | — |
| Fiscal year | FY2007 | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $245M | $222M | $301M | $523M | $457M | $688M | $683M | $634M | $550M | $747M |
| Total assets | — | $14.9B | $15.8B | $17.1B | $19.5B | $22.3B | $23.1B | $25.4B | $25.4B | $26.9B |
| Total liabilities | — | $8.80B | $8.79B | $9.29B | $11.1B | $12.6B | $13.0B | $14.5B | $13.8B | $14.2B |
| Long-term debt | — | — | — | $4.31B | $5.49B | $7.79B | $7.75B | $9.01B | $7.85B | $7.20B |
| Shareholders' equity | $5.68B | $5.96B | $6.82B | $7.38B | $7.90B | $8.94B | $9.23B | $9.44B | $9.89B | $10.8B |
| Retained earnings | — | $2.45B | $3.11B | $3.86B | $4.65B | $5.56B | $6.38B | $7.10B | $7.87B | $8.84B |
| Shares (wtd avg diluted) | — | — | 296M | 298M | 300M | 300M | 301M | 301M | 305M | 306M |
Every figure is extracted from Fresenius Medical Care AG’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.